PACTG 1020-A: NOVEL PROTEASE INHIBITOR (BMS-232632) IN HIV-INFECTED CHILDREN

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项多中心I/II期开放式研究，研究了一种新的蛋白酶抑制剂(BMS-232632)，用于感染HIV-1的儿科患者。各种各样的具有不同类型的治疗抵抗的患者(不包括顺应性)都有资格参加。BMS-232632是一种C2对称的氮杂肽，在结构上不同于特许的蛋白酶抑制剂，后者是模拟多肽的。到目前为止，对成年人的主要毒性是高胆红素血症。参加这项研究的人数仍在继续。目前还没有结果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multicenter phase I/II open-label study of a novel protease inhibitor (BMS-232632) in HIV-1-infected pediatric patients. A wide variety of patients with varying types of therapeutic resistance (excepting noncompliance) are eligible for enrollment. BMS-232632 is a C2-symmetrical azapeptide structurally different from licensed protease inhibitors, which are peptidomimetic. The major toxicity to date in adults has been hyperbilirubinemia. Enrollment into this study continues. Results are not yet available.